LAS41003 clinical trials
Also written LAS41003.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses LAS41003 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LAS41003
- 3
Studies by the year they started
3 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses LAS41003 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea PedisCompletedPhase 2Almirall, S.A.NCT01096472Written as LAS41003
- Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida InfectionsCompletedPhase 2Almirall, S.A.NCT01102387Written as LAS41003
- Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected EczemaCompletedPhase 2Almirall, S.A.NCT01020994Written as LAS41003